<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451048</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00211</org_study_id>
    <secondary_id>PHL-063</secondary_id>
    <secondary_id>CDR0000535656</secondary_id>
    <secondary_id>N01CM62203</secondary_id>
    <nct_id>NCT00451048</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>A Phase II Study of Sunitinib Malate (SutentÂ®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well sunitinib works in treating patients with
      myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth
      of abnormal cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the overall response rate (complete response, partial response, or hematological
      improvement) in patients with intermediate-2 or high-risk myelodysplastic syndromes or
      chronic myelomonocytic leukemia treated with sunitinib malate.

      II. Determine the duration of response in patients treated with this drug. III. Determine the
      overall survival of patients treated with this drug. IV. Determine the progression-free
      survival of patients treated with this drug. V. Determine the time to disease progression in
      patients treated with this drug.

      VI. Determine the toxicity of this drug in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 4 weeks
      in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed at 3-4 weeks and then monthly
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Observed Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MDS syndromes meeting 1 of the following: Intermediate-2 disease, high-risk disease
             (IPSS score&gt;=1.5)

          -  CMML: WBC&gt;12,000/mm^3, Intermediate-2 disease with WBC=&lt;12,000/mm^3, high-risk disease
             (IPSS score&gt;=1.5) with WBC=&lt;12,000/mm^3

          -  Patients with insufficient/inadequate metaphases for cytogenetic analysis are eligible
             if bone marrow blasts are &gt;10% and/or 2-3 cytopenias are present

          -  No known brain metastases

          -  Life expectancy&gt;12 weeks

          -  ECOG PS 0-2/Karnofsky PS 60-100%

          -  Calcium=&lt;3.0 mmol/L

          -  Bilirubin normal

          -  AST and ALT=&lt;2.5 times upper limit of normal

          -  Creatinine normal/creatinine clearance&gt;=60 mL/min

        Exclusion Criteria:

          -  No history of significant ECG abnormalities including but not limited to: ventricular
             arrhythmias (ventricular tachycardia, ventricular fibrillation&gt;=3 beats in a row); QTc
             prolongation (i.e.QTc interval&gt;=500msec)

          -  No history of allergic reaction to compounds of similar chemical/biological
             composition to sunitinib malate

          -  No NYHA class III-IV congestive heart failure

          -  Patients with history of NYHA class II congestive heart failure who are asymptomatic
             on treatment are eligible

          -  No abdominal fistula/G perforation/intraabdominal abscess within past 28 days

          -  No serious cardiovascular disease within past 12 months including: cerebrovascular
             accident or transient ischemic attack, myocardial infarction, cardiac arrhythmia,
             stable or unstable angina, symptomatic congestive heart failure, coronary or
             peripheral artery bypass graft or stenting

          -  No pulmonary embolism within past 12 months

          -  No uncontrolled hypertension (systolic BP&gt;=140 mmHg/diastolic BP&gt;=90 mmHg)

          -  No condition impairing ability to swallow/retain sunitinib malate tablets including:
             GI tract disease resulting in inability to take oral medication, requirement for IV
             alimentation, prior surgical procedures affecting absorption, active peptic ulcer
             disease

          -  No serious/nonhealing wound, ulcer, or bone fracture

          -  No uncontrolled pre-existing thyroid abnormality

          -  No concurrent uncontrolled illness including ongoing/active infection

          -  No psychiatric illness/social situation that would preclude study participation

          -  Not pregnant/nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception

          -  4 weeks since prior major surgery

          -  Prior central thoracic radiotherapy that included heart in radiotherapy port allowed
             provided NYHA congestive heart failure=&lt;class II

          -  Prior anthracycline exposure allowed provided NYHA congestive heart failure=&lt;class II

          -  No other prior therapy for MDS/CMML except epoetin alfa, darbepoetin alfa, filgrastim
             or sargramostim

          -  At least 2 weeks since prior epoetin alfa

          -  At least 4 weeks since prior darbepoetin alfa

          -  No other prior antiangiogenic agents including but not limited to: bevacizumab,
             sorafenib tosylate, pazopanib hydrochloride, AZD2171, vatalanib, VEGF Trap

          -  More than 7 days since prior and no concurrent potent CYP3A4 inhibitors

          -  More than 12 days since prior and no concurrent potent CYP3A4 inducers including:
             Rifampin, Rifabutin, Carbamazepine, Phenobarbital, Phenytoin, Hypericum perforatum,
             Efavirenz, Tipranavir

          -  No concurrent birth control patch/oral birth control pills/depot/injectable birth
             control methods

          -  No concurrent therapeutic coumarin-derivative anticoagulants

          -  Low dose(=&lt;2mg) warfarin for prophylaxis of thrombosis allowed

          -  Low molecular weight heparin allowed if INR=&lt;1.5

          -  No concurrent agents with proarrhythmic potential including: Terfenadine, Quinidine,
             Procainamide, Disopyramide, Sotalol, Probucol, Bepridil, Haloperidol, Risperidone,
             Indapamide, Flecainide acetate

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Yee</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre- Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.
sunitinib malate: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.
sunitinib malate: Given orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="62" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria</title>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>Up to 6 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>At 6 months and 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>At 6 months and 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <time_frame>At 6 months and 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Observed Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0)</title>
        <time_frame>Up to 6 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.
sunitinib malate: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen Yee</name_or_title>
      <organization>Princess Margaret Hospital</organization>
      <phone>416-946-4495</phone>
      <email>karen.yee2@uhn.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

